{"schema_version":"1.0","type":"article","title":"RAS Targeting Opens a New Pancreatic-Cancer Window: How Senhwa's CX-5461 Positions for the Next Resistance-Management War","url":"https://drugnews.com.tw/articles/2026-06-10-sinphar-cx5461-ras-pancreatic-cancer-en.html","markdown_url":"https://drugnews.com.tw/articles/2026-06-10-sinphar-cx5461-ras-pancreatic-cancer-en.md","lang":"en","date":"2026-06-10","publish_at":"2026-06-10T10:45:00+08:00","updated_at":"2026-06-10","category":"商業分析系列","topic":"公司研究","tags":["Company Research","Biotech business analysis","Drug development"],"summary":"Daraxonrasib opens a new pancreatic-cancer window, but the next value question is resistance management. Senhwa's CX-5461 matters if it can become a rational combination partner.","key_points":[],"facts":[],"sections":["01｜After RAS is suppressed, where will the cancer cells escape?","02｜CX-5461: Not replacing RAS inhibitors, but adding to the resistance puzzle","03｜Changing the tumor from cold to hot is the key to immunotherapy of pancreatic cancer","04｜Multiple pathways of pressure create a higher threshold for drug resistance","05｜FDA agrees to accept the design, the significance is to \"enter the real drug resistance scenario\"","06｜Not only pancreatic cancer, HRD and PARP resistance are also another value line","07｜Three nodes that Sheng Huake really needs to look at","Conclusion｜RAS inhibitors open the door, CX-5461 wants to defend the next drug resistance barrier"],"references":[],"images":[{"alt":"RAS Opens the Door","url":"https://drugnews.com.tw/assets/articles/sinphar-cx5461-ras-pancreatic-cancer-en/figure-01.png"},{"alt":"Escape Pathways","url":"https://drugnews.com.tw/assets/articles/sinphar-cx5461-ras-pancreatic-cancer-en/figure-02.png"},{"alt":"CX-5461 Positioning","url":"https://drugnews.com.tw/assets/articles/sinphar-cx5461-ras-pancreatic-cancer-en/figure-03.png"},{"alt":"What to Track","url":"https://drugnews.com.tw/assets/articles/sinphar-cx5461-ras-pancreatic-cancer-en/figure-04.png"}],"cover_image":"https://drugnews.com.tw/assets/articles/sinphar-cx5461-ras-pancreatic-cancer-en/cover.png","publisher":{"name":"Drugnews｜藥時事","url":"https://drugnews.com.tw/","profile":"https://drugnews.com.tw/brand-profile.json"},"citation":"Drugnews｜藥時事（2026-06-10）。RAS Targeting Opens a New Pancreatic-Cancer Window: How Senhwa's CX-5461 Positions for the Next Resistance-Management War。https://drugnews.com.tw/articles/2026-06-10-sinphar-cx5461-ras-pancreatic-cancer-en.html","disclaimer":"This article is intended for industry research and knowledge sharing only. It does not constitute investment, medical, fundraising, or individual stock advice.","translations":{"zh-Hant":"2026-06-10-sinphar-cx5461-ras-pancreatic-cancer.html"},"relationship":"independent_editorial","disclosure_url":"https://drugnews.com.tw/policy/"}